Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class drugs.
Gerresheimer is a German contract organisation for medicine packaging and drug delivery devices. In February, the manufacturer reported an expected average growth of 10% per year, with almost half of the growth associated with services for GLP-1 class drugs.
Siemssen states that he expects GLP-1 medicine-related sales to exceed EUR100 million in 2024 alone. This number is expected to reach EUR350 million in the next 3 years based on current actual contracts and orders. Siemssen states, “We are just at the beginning of the ramp-up towards the total market for these drugs, and the biggest growth will be from 2025 to 2027.”
As the weight-loss drug market continues to explode – estimates place it at reaching US$100 billion a year by 2030 – both drugmakers and pharma contract organisations are racing to secure their piece of the pie. Earlier in March, Novo Nordisk’s biggest shareholder, Novo Holdings, announced their acquisition of CDMO Catalent. While such acquisitions of contract manufacturers do not necessarily spell out a trend for the pharma industry, many deals and contracts between drug sponsors and vendors are expected to increase growth for those striking partnerships with obesity drugmakers. Gerresheimer is already manufacturing injection pens for both Novo Nordisk and Eli Lilly, the leading pharma companies in the obesity drug market. A dual-chamber syringe manufactured by Gerresheimer will be used by Novo for the obesity drug cagrisema from April 2024.
Additionally, Gerresheimer has been manufacturing products for GLP-1 drugs in Germany and Mexico, and injectable pens for other drug products in the Czech Republic, South America, and the US. Siemssen comments, “The Mexican plant will not only host GLP-1 products, but will be our key facility for the North American markets.” The German manufacturer has also released plans for a manufacturing facility in the US to begin producing products and services for GLP-1 drugs in autumn of 2025. Last year, the company recorded US$2.15 billion in sales, with revenue growth of 5–10% in 2024 and 10–15% in 2025.
Sources:
1. Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says [Accessed April 2, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drug-deals-drive-around-4-gerresheimer-yearly-growth-ceo-says-2024-03-29/
2. Wegovy® – the weight-loss drug sparking a global race to end obesity [Accessed April 2, 2024] https://www.cphi-online.com/wegovy-the-weight-loss-drug-sparking-a-global-news123796.html
Related News
-
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Wegovy® – the weight-loss drug sparking a global race to end obesity
Wegovy®, the weight loss drug from Novo Nordisk has been creating headlines since it’s early testing phases, through it’s approval in June 2021 by the US FDA and January 2022 from the European Medicines Agency, and it continues to do so... -
News US FDA approves three different oncology drugs in 1 week
In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications. -
News What the Novo Holdings and Catalent deal means for pharma outsourcing
On February 5, 2024, Novo Holdings announced their intention to acquire pharma and biotech CDMO Catalent at US$16.5 billion. Read more about what this means for the pharmaceutical industry as a whole, from drugmakers to their partners in manufacturing....
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance